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Abstract
Background: Exposure to air pollution has been implicated in a number of adverse health outcomes and the effect
of particulate matter (PM) on the brain is beginning to be recognized. Yet, no prospective study has examined the
association between PM and risk of Parkinson Disease. Thus, our goal was assess if exposure to particulate matter
air pollution is related to risk of Parkinson’s disease (PD) in the Nurses’ Health Study (NHS), a large prospective
cohort of women.
Methods: Cumulative average exposure to different size fractions of PM up to 2 years before the onset of PD, was
estimated using a spatio-temporal model by linking each individual’s places of residence throughout the study with
location-specific air pollution levels. We prospectively followed 115,767 women in the NHS, identified 508 incident
PD cases and used multivariable Cox proportional hazards models to estimate the risk of PD associated with each
size fraction of PM independently.
Results: In models adjusted for age in months, smoking, region, population density, caffeine and ibuprofen intake,
we observed no statistically significant associations between exposure to air pollution and PD risk. The relative risk
(RR) comparing the top quartile to the bottom quartile of PM exposure was 0.99 (95% Confidence Intervals (CI):
0.84,1.16) for PM10 (≤10 microns in diameter), 1.08 (95% CI: 0.81, 1.45) for PM2.5 (≤2.5 microns in diameter), and 0.92
(95% CI: 0.71, 1.19) for PM10–2.5 (2.5 to 10 microns in diameter).
Conclusions: In this study, we found no evidence that exposure to air pollution is a risk factor for PD.
Keywords: Epidemiology, Cohort studies, Incidence studies, Parkinson disease/Parkinsonism
Background
Chronic exposure to air pollution has detrimental effects
on human health [1-3]. However, little is known about
the effects of air pollution on neurological outcomes and
risk of Parkinson’s disease (PD). The existence of a link
between air pollution and PD risk is suggested by the
observations that toxins in air pollution evoke a systemic
inflammatory response and oxidative stress [4], markers
of which have been shown in some studies to be elevated
among PD patients [5]. The brain is particularly vulnerable
to oxidative stress, due it’s high consumption of oxygen,
low level of antioxidants, high levels of polyunsaturated
fatty acids and elevated iron content (particularly in the
substantia nigra, a key brain area for PD) [6]. Further, in-
creased plasma levels of inflammatory markers have been
associated in some studies [7,8], whereas higher urate, a
potent antioxidant, appears to have neuroprotective effects
in experimental models [9,10] and is associated with lower
PD risk [11-13]. In a recent analysis, Willis et al. linked En-
vironmental Protection Agency (EPA) data on lead, copper
and mercury emissions with the Medicare dataset on the
county level throughout the US, and showed increased risk
of PD among participants living in urban counties with the
highest reported emissions of copper and manganese [14].
An adverse effect of air pollution would be consistent with
evidence that in some cases PD may originate in the ol-
factory bulb and may thus be caused by a pathogen that
enters the body through the nasal pathway [15,16]. We
thus examined in a large prospective study of US nurses,
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associated with increased risk of PD.
Methods
We examined the effects on PD risk of exposure to par-
ticulate matter less than or equal to 10 microns (PM10),
less than or equal to 2.5 microns (PM2.5), and between
2.5 and 10 microns in diameter (PM10–2.5) in a large pro-
spective cohort of older women with biennially updated
addresses living throughout the contiguous United States.
This study was approved by the Brigham and Women’s
Hospital IRB.
Study population
Since 1976, 121,700 female registered nurses have been
participating in the Nurses’ Health Study (NHS). The
participants were recruited from 11 states (California,
Connecticut, Florida, Maryland, Massachusetts, Michigan,
New York, New Jersey, Pennsylvania, Ohio and Texas) and
were between 30 and 55 years old at baseline. At baseline
and every two years thereafter, participants received, at
their residential address, questionnaires asking about life-
style factors and health outcomes. A question regarding
PD was first asked in 1994. The follow-up rate in the NHS
has been above 90% for each follow-up cycle. Detailed de-
scription of the study cohort is provided elsewhere [17].
The Institutional Review Board (IRB) at the Brigham and
Women’s Hospital approved this study.
Exposure assessment
Monthly exposures to ambient air pollution were esti-
mated for each participant using spatio-temporal models,
discussed in detail elsewhere [18-20]. In brief, generalized
additive models of PM10 from 1988 through 2007 were de-
veloped [19] for the continental United States (US), using
monthly average PM10 data from EPA’s Air Quality System
(AQS), a nationwide network of continuous and filter-
based monitors, as well as data from various other sources,
including the Interagency Monitoring of Protected Visual
Environments (IMPROVE) network, and several Harvard-
based research studies. A geographic information system
(GIS) was used to derive the following model covariates:
population density, distance to nearest road, elevation, and
urban land use. The estimation of PM2.5 was similar; how-
ever, because EPA AQS monitoring data for PM2.5 was not
available prior to 1999, separate models were created for
pre- and post-1999 PM2.5. To estimate PM2.5 prior to
1999, the model relied on measured PM10 pre-1999 and
the PM2.5 to PM10 ratio from the spatio-temporal model
post-1999, as well as estimated extinction coefficients from
airport visibility data. PM10–2.5 was estimated by subtract-
ing values for PM2.5 from those for PM10. All models
s h o w e dl i t t l eb i a sa n dah i g hd e g r e eo fp r e c i s i o nw h e n
evaluated with a cross-validation approach, where a sub-
section of the monitors were held out to compare pre-
dicted and observed values [19,20].
PD Ascertainment
The method used to ascertain PD cases has been de-
scribed previously [21]. Briefly, since 1994, new cases of
PD in the NHS have been identified through biennial
questionnaires. When a participant reports PD, con-
sent is sought from the participant to contact their treat-
ing neurologist (or internist if the neurologist is not
available) and upon receipt of the consent the doctor is
contacted to complete a questionnaire to confirm the
diagnosis of PD and send a copy of the medical records.
Of the self-reported PD cases in the NHS, we were able
to contact 86% and of those, 69% provided consent to
review medical records (17% did not give permission
and 14% denied the diagnosis of PD). The medical re-
cords are reviewed by a movement disorder specialist
(M.A.S.) blinded to the exposure status. A case is con-
sidered confirmed if the treating physician reported it as
either definite or probable, or if the medical record in-
cluded evidence of either a final diagnosis of PD made
by a neurologist or evidence of two or more of the three
cardinal signs of PD (bradykinesia, rigidity, rest tremor)
in the absence of characteristics suggesting an alternate
diagnosis. The main analyses were performed among
confirmed cases. We performed sensitivity analyses in-
cluding participants who reported PD but did not give
consent to review their medical records. Of the 508 inci-
dent PD cases included in this study, 212 were definite
and 296 were probable cases.
Statistical analysis
Cox proportional hazards models with age as the time
scale were used to model the association between expos-
ure to PM10, PM2.5, PM10–2.5, and PD. Person-months of
follow-up were calculated from baseline (June 30, 1990,
to allow for a 2-year lag prior to the first incident PD
cases reported in this study) through the end of follow-up
(June 30, 2008), death or date of PD diagnosis, whichever
occurred earlier. Exposure to air pollution was included in
the models as a time-dependent variable that was incre-
mented each month. We focused on the cumulative aver-
age exposure to PM10,P M 2.5 and PM10–2.5 up to 2 years
before PD diagnosis to best capture any effects of air
pollution before the onset of PD. In separate models,
we also considered a lag of 5 years prior to diagnosis, as
well as using PM exposure in 2000, when the PM data
is most complete (results not shown). Analyses were ad-
justed for age in months, region of the United States
(northeast,/midwest/west/south), pack years smoking,
smoking status (never/past/current), population density,
caffeine consumption and use of ibuprofen. Regarding
ibuprofen use, our questionnaire asked the following
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you take the following medicine (ibuprofen)”,a n dt h e
responses were never, 1–4 days, 5–14 days, 15–21 days,
and 22 or more days. Participants taking the drug 1 or
more days per month were considered ever users for
the purpose of this study. We also conducted additional
analyses adjusting for tract-level income and housing
value, as taken from the 2000 US census [22]. These
were included in models as time-dependent variables.
Because dietary, lifestyle and geographic factors may
modify the relationship between air pollution and PD,
we conducted additional analyses, stratified by smok-
ing, caffeine intake and ibuprofen use, the main known
factors related to PD risk, as well as region of the US
(as the pollutant type and thus the effect on PD may
differ by region). For tests of trend, the median value in
each quintile was used as a continuous variable to allow
for nonlinear associations. SAS version 9.1 (SAS Insti-
tute, Cary, NC, USA) was used for the statistical
analyses.
Results
Table 1 shows the baseline characteristics of the study
population. There were 115,620 participants in the study
at baseline, and 508 incident PD cases included in pro-
spective analyses. The characteristics of the PD cases in-
cluded in the study were as follows: the mean age at PD
onset was 71 years, 30% were current smokers at base-
line, 28% were ever users of ibuprofen (using one or
more times per month), and the mean baseline caffeine
among intake was 231 mg/day. The average follow-up
for participants included in the analyses was 16.6 years
(SD: 3.5 years). All three measures of air pollution were
positively associated with population density. PM10 was
Table 1 Age-standardized characteristics of the 111,769 study participants at baseline in 1990 with respect to
categories of PM10
PM10
Pollution category Q1* Q2 Q3 Q4
Median PM
a 19.0 22.6 26.0 31.8
Age, mean (sd) 58.2 (7.2) 58.2 (7.2) 58.1 (7.2) 58.2 (7.2)
Never Smoker (%) 48.0 46.5 45.9 42.3
Pack years, mean (sd) 12.8 (19.3) 13.1 (19.4) 13.0 (19.1) 13.9 (19.5)
Caffeine mg/day, mean (sd) 284.2
(239.5) 284.6
(238.1) 280.2
(234.1) 274.8
(228.2)
Ibuprofen ever user (%) 28.7 28.4 28.7 26.8
Census tract income
b, USD, mean (sd) 51602.9
(16926) 58044.3
(22510.2) 66772.3
(26322.7) 66,772.3
(26322.7)
(Population density)
b, (persons/tract), mean, (sd) 1436.3
(2184.5) 2139.3
(3216.8) 1922.6
(3088.5) 4449.4
(9575.1)
Region of US
‘Northeast Region 12.2 18.5 41.8 61.2
‘Midwest region’, % 31.8 26.2 27.2 14.7
‘West region’, % 7.0 3.5 6.7 15.9
‘South region’, % 49.0 51.8 24.3 8.2
*Q (1,2,3,4) - quartiles – categories (C1, C2, C3 and C4) for distance to road as shown in Table 3.
g/day: grams/day.
aμg/m
3 (PM).
btract-level variable based on the 2000 US Census.
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and 0.82); however, PM2.5 and PM10–2.5 were not highly
correlated (r= 0.26).
We found no statistically significant associations be-
tween air pollution and PD risk. The relative risk (RR)
comparing the top quartile to the bottom quartile of PM
exposure was 0.99 (95% Confidence Intervals (CI):
0.84,1.16) for PM10, 1.08 (95% CI: 0.81, 1.45) for PM2.5,
and 0.92 (95% CI: 0.71, 1.19) for PM10–2.5. These results
are shown in Table 2.
In stratified analyses, we did not observe any statistically
significant interactions with smoking caffeine consumption
and PM exposure (Table 3). The effect of PM on PD risk
did not differ significantly by region of the US.
Our analyses did not differ notably with additional ad-
justment for tract-level income and housing value. Ana-
lyses using pollution values in 2000 as the exposure and
lagging PM exposure by 5 years with respect to PD onset
also did not differ materially from the primary analyses.
Analyses that also included cases that did not confirm
their diagnosis of PD cases were similar to the main
analyses. We conducted additional sensitivity analyses
among non-movers (Table 4), the results of which were
not significantly different from those of our main
analyses.
Discussion
In this study, we did not observe a statistically significant
increase in PD risk associated with exposure to ambient
air pollution measured as cumulative exposure to PM2.5,
PM10 and PM10–2.5 at the residential address. We did
not observe any interaction with smoking or caffeine for
any of the size fractions. An interaction was observed
between PM10 and PM10–2.5 and use of ibuprofen, but
this this was an unexpected finding and could have oc-
curred by chance.
PM10 includes all particles smaller than 10 microns in
diameter; a size considered to be small enough to pass
through the throat or the nose and enter the lungs, thus
potentially causing harm to human health. PM10 in-
cludes inhalable coarse particles (PM10–2.5) and fine par-
ticles (PM2.5). Inhalable coarse particles, PM10–2.5 comes
primarily from agricultural, mining and construction
sources [23]. Fine particles, PM2.5, consists primarily of
combustion particles from the burning of coal, wood
and fuel oil and from motor vehicle emissions [23]. Ex-
posure to PM has been associated with many harmful ef-
fects on human health. The Harvard Six Cities Study [1]
and the American Cancer Society Study [2] were the
first major studies to link exposure to air pollution to all
cause mortality (The RR for all cause mortality in the
Table 2 Exposure to PM10, PM2.5, and PM10–2.5 and risk of PD in the Nurses’ Health Study, 1990–2008 (N=111,769
women at baseline)
Age adjusted Multivariate
a
PY Cases RR 95% CI RR 95% CI P-trend
Quartiles of PM10
3.8-21.0 μg/m
3 484444 141 1.00 Ref 1.00 Ref
21.0– 24.3 μg/m
3 484483 135 1.06 (0.83, 1.34) 1.09 (0.86, 1.39)
24.3 – 28.3 μg/m
3 484520 120 1.02 (0.80, 1.30) 1.03 (0.80, 1.32)
28.3 – 88.3 μg/m
3 484550 112 1.03 (0.80, 1.32) 1.03 (0.78, 1.37) 0.92
Continuous^ PM10 1937996 508 0.99 (0.86, 1.12) 0.99 (0.84, 1.16)
Quartiles of PM2.5
1.2-12.6 μg/m
3 484429 131 1.00 Ref 1.00 Ref
12.6-15.0 μg/m
3 484482 131 1.12 (0.88, 1.43) 1.07 (0.83, 1.38)
15.0-17.4 μg/m
3 484513 137 1.23 (0.97, 1.57) 1.14 (0.88, 1.48)
17.4-73.9 μg/m
3 484573 109 1.17 (0.90, 1.51) 1.10 (0.83, 1.45) 0.43
Continuous^ PM2.5 1937996 508 1.17 (0.90-1.51) 1.08 (0.81-1.45)
Quartiles of PM10–2.5
0-7.2 μg/m
3 484479 149 1.00 (Ref) 1.00 (Ref)
7.2-9.2 μg/m
3 484496 121 0.87 (0.69, 1.11) 0.91 (0.71, 1.16)
9.2-12.0 μg/m
3 484495 119 0.87 (0.68, 1.11) 0.93 (0.72, 1.20)
12.0-67.1 μg/m
3 484506 119 0.87 (0.68, 1.11) 0.93 (0.69, 1.26) 0.64
Continuous^ PM10–25 1937996 508 0.90 (0.74-1.09) 0.92 (0.71-1.19)
PY: person years; RR: relative risk; 95% CI: 95 percent confidence interval.
aadjusted for age, smoking, region (northeast, midwest, west, and south), population density, caffeine intake (<100 mg/day vs. over 100 mg/day) and ibuprofen
use (ever/never user).
^per 10 μg/m
3.
Palacios et al. Environmental Health 2014, 13:80 Page 4 of 9
http://www.ehjournal.net/content/13/1/80Table 3 Exposure to PM and risk of PD in the Nurses’ Health Study, 1990–2008 (N= 111,769) by smoking status,
caffeine intake and ibuprofen use
PY Cases RR
a 95% CI PY Cases RR
a 95% CI p-int
By smoking status: Never smokers Ever smokers
Quartiles of PM10
Q1 206697 73 1.00 Ref 278761 68 1.00 Ref
Q2 209774 75 1.14 (0.82, 1.58) 275654 60 1.03 (0.72, 1.47)
Q3 213834 63 0.99 (0.70, 1.41) 271618 57 1.05 (0.73, 1.52)
Q4 213834 56 0.92 (0.62, 1.36) 265933 56 1.14 (0.76, 1.71) 0.31
Continuous* PM10 849835 267 0.96 (0.85, 1.09) 1091965 241 1.04 (0.92, 1.18) 0.42
Quartiles of PM2.5
Q1 210817 69 1.00 Ref 274637 62 1.00 Ref
Q2 204967 69 1.07 (0.76, 1.52) 280601 62 1.06 (0.74, 1.54)
Q3 214387 70 1.07 (0.74, 1.53) 271003 67 1.21 (0.84, 1.76)
Q4 219664 59 1.06 (0.72, 1.55) 265724 50 1.12 (0.74, 1.69) 0.58
Continuous* PM2.5 849835 267 1.01 (0.90, 1.15) 1091965 241 1.05 (0.92, 1.19) 0.66
Quartiles of PM10–2.5
Q1 212002 85 1.00 Ref 273461 64 1.00 Ref
Q2 204860 60 0.79 (0.57, 1.11) 280562 61 1.05 (0.74, 1.51)
Q3 210385 58 0.77 (0.54, 1.09) 274925 61 1.14 (0.79, 1.65)
Q4 222580 64 0.82 (0.54, 1.24) 263007 55 1.05 (0.67, 1.65) 0.26
Continuous^ PM10–25 849835 267 0.93 (0.81, 1.05) 1091965 241 1.03 (0.90, 1.18) 0.41
By Caffeine intake: <100 mg/day caffeine > =100 mg/day caffeine
Quartiles of PM10
Q1 196761 69 1.00 Ref 287683 72 1.00 (Ref)
Q2 189470 69 1.20 (0.85, 1.68) 295013 66 0.99 (0.70, 1.40)
Q3 189270 73 1.35 (0.95, 1.91) 295251 47 0.74 (0.50, 1.08)
Q4 184296 57 1.20 (0.81, 1.78) 300254 55 0.87 (0.60, 1.31) 0.23
Continuous* PM10 759796 268 1.08 (0.95, 1.22) 1178200 240 0.93 (0.81, 1.06) 0.49
Quartiles of PM2.5
Q1 194876 65 (Ref) 289553 66 1.00 (Ref)
Q2 189312 68 1.02 (0.71, 1.46) 295169 63 0.77 (0.53, 1.10)
Q3 194935 74 1.06 (0.73, 1.55) 289578 63 0.86 (0.60, 1.24)
Q4 180673 61 0.88 (0.58, 1.32) 303900 48 0.69 (0.44, 1.09) 0.22
Continuous* PM25 759796 268 0.97 (0.85, 1.10) 120299 240 0.91 (0.79, 1.04) 0.38
Quartiles of PM10–2.5
Q1 196694 76 1.00 (Ref) 287785 73 1.00 (Ref)
Q2 185789 67 1.05 (0.75, 1.47) 298707 54 0.77 (0.53, 1.10)
Q3 188793 59 0.99 (0.70, 1.43) 295702 60 0.86 (0.60, 1,24)
Q4 188513 66 1.20 (0.79, 1.80) 295993 53 0.69 (0.44, 1.09) 0.45
Continuous^ PM10–25 759796 268 1.04 (0.92, 1.19) 1178200 240 0.91 (0.79, 1.04) 0.72
By use of ibuprofen Never user Ever user
Quartiles of PM10
Q1 378733 101 1.00 (Ref) 105711 40 1.00 (Ref)
Q2 375957 110 1.22 (0.93, 1.61) 108526 25 0.76 (0.45, 1.26)
Q3 373161 87 1.04 (0.77, 1.40) 111359 33 1.03 (0.63, 1.68)
Q4 369737 95 1.20 (0.87, 1.65) 114813 17 0.62 (0.33, 1.16) 0.04
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1.16 (95% CI: 1.07-1.26) [24]). Since then, many more
studies have documented the detrimental effects of
chronic exposure to air pollution on human health and
survival [24,25].
Prior work on air pollution and PD has been limited.
Finkelstein and colleagues [26], found that although
markers of traffic derived air pollution did not predict
PD risk, risk was increased among participants with
higher Manganese (Mn) exposure (RR: 1.03; 95% CI:
1.00-1.07) for each 10 ng/m
3 increase in Mn concentra-
tion) [26]. In a recent study that used GIS to link air-
borne metal exposure data throughout the US to the
Medicare beneficiaries database, Willis and colleagues
found a higher incidence of PD in urban counties with
higher industrial release of copper and manganese [14].
Also, a number of studies have linked occupational manga-
nese exposure to risk of Parkinsonian syndromes [27,28]
although this is thought to be distinct from PD [29].
Our study’s estimates of PM air pollution have an ad-
vantage over what was done in prior studies because
the measures are based on a comprehensive prediction
model of PM. This model allows us to estimate air pol-
lution levels for an entire cohort of non-occupationally
exposed participants at each participant’s residential ad-
dress. Also, our air pollution models used GIS-based
spatio-temporal statistics with GIS covariates that allow
us to account for small-scale variations in pollution
around each woman’sa d d r e s sa n dt oe s t i m a t et h ep o l -
lution level for each address that each study participant
has reported during the study period, thus giving us a
Table 3 Exposure to PM and risk of PD in the Nurses’ Health Study, 1990–2008 (N= 111,769) by smoking status,
caffeine intake and ibuprofen use (Continued)
Continuous* PM10 1491149 375 1.04 (0.04, 1.15) 440409 115 0.91 (0.75, 1.10) 0.03
Quartiles of PM2.5
Q1 377642 101 1.00 (Ref) 106787 30 1.00 (Ref)
Q2 376538 103 1.16 (0.87, 1.55) 107943 28 0.81 (0.47, 1.37)
Q3 375892 98 1.13 (0.84, 1.52) 108622 39 1.14 (0.68, 1.91)
Q4 367516 91 1.26 (0.87, 1.55) 117056 18 0.64 (0.34, 1.20) 0.43
Continuous* PM25 1491149 393 1.07 (0.97, 1.18) 440409 115 0.93 (0.77, 1.12) 0.38
Quartiles of PM10–2.5
Q1 375666 107 1.00 Ref 108813 42 1.00 (Ref)
Q2 374592 90 0.92 (0.70, 1.23) 109905 31 0.81 (0.50, 1.30)
Q3 375149 98 1.02 (0.77, 1.35) 109346 21 0.56 (0.33, 0.96)
Q4 372167 98 1.01 (0.76, 1.36) 112339 21 0.55 (0.32, 0.97) 0.01
Continuous^ PM10–25 1497588 393 1.01 (0.92, 1.11) 440409 115 0.80 (0.67, 0.96) 0.01
Abbreviations: PY person years; RR relative risk; 95% CI 95 percent confidence interval.
aadjusted for age, smoking (except in smoking stratified analyses), region (northeast, midwest, west, and south), population density, caffeine intake (<100 mg/day
vs. over 100 mg/day, except in caffeine stratified analyses) and ibuprofen use (ever/never user, except in ibuprofen stratified analyses).
^per 10 μg/m
3.
Table 4 Exposure to PM10, PM2.5, and PM10–2.5 and risk of
PD in the Nurses’ Health Study among non-movers,
1990–2008 (N= 80,544 women at baseline who did not
move during the study)
Multivariate
a
PY Cases RR 95% CI P-trend
Quartiles of PM10
3.8-21.0 μg/m
3 395353 123 1.00 Ref
21.0– 24.3 μg/m
3 395383 115 1.09 (0.84, 1.41)
24.3 – 28.3 μg/m
3 395419 100 1.00 (0.76, 1.33)
28.3 – 88.3 μg/m
3 395426 90 0.98 (0.76, 1.33) 0.92
Continuous^ PM10 1581580 430 0.99 (0.89, 1.09)
Quartiles of PM2.5
1.2-12.6 μg/m
3 395343 110 1.00 Ref
12.6-15.0 μg/m
3 395383 111 1.10 (0.83, 1.45)
15.0-17.4 μg/m
3 395409 121 1.25 (0.94, 1.65)
17.4-73.9 μg/m
3 395446 88 1.11 (0.81, 1.52) 0.43
Continuous^ PM2.5 158446 430 1.08 (0.81-1.45)
Quartiles of PM10–2.5
0-7.2 μg/m
3 395375 132 1.00 (Ref)
7.2-9.2 μg/m
3 395394 106 0.93 (0.71, 1.21)
9.2-12.0 μg/m
3 395397 96 0.90 (0.68, 1.20)
12.0-67.1 μg/m
3 395395 96 0.90 (0.63, 1.28) 0.64
Continuous^ PM10–25 1937996 430 0.95 (0.85-1.05)
PY: person years; RR: relative risk; 95% CI: 95 percent confidence interval.
aadjusted for age, smoking, region (northeast, midwest, west, and south),
population density, caffeine intake (<100 mg/day vs. over 100 mg/day) and
ibuprofen use (ever/never user).
^per 10 μg/m
3.
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Animal studies suggest that PM may access the brain
either through the nasal pathway or through the circula-
tion [15,16,23,30]. Fine particles in the central nervous
system have been associated with increased brain inflam-
mation in several studies [31-33]. In one study, levels of
several pro-inflammatory cytokines were elevated in the
brains of mice exposed to high levels of particulate mat-
ter compared to controls [31]. In another study in rats,
exposure to diesel exhaust was associated with an in-
crease of a number of inflammatory factors, including
whole-brain IL-6 and TNF α, among others [34]. Fur-
thermore, a study of Mexico city residents, showed
higher levels of neuroinflammation of the olfactory bulb
(as indicated by higher levels of COX 2 and IL1β) and
higher concentrations of metals associated with PM (in-
cluding manganese, nickel and chromium) among inhab-
itants of urban areas [35]. A study using autopsies of
brains from children and young adults in Mexico City,
Mexico found elevation of indices on neuroinflammation
and oxidative stress in the brains of participants exposed
to high levels of particulate matter [36]. Higher levels of
inflammatory factors in the brain have been linked with
increased risk of PD in several studies. PD patients had
significantly higher levels of oxidized –LDL and high-
sensitivity of C-reactive protein (both markers of inflam-
mation) compared to controls in one study [5,7], and el-
evated levels of Il-6, but not CRP in another study [7].
Measurement of long-term exposure to air pollution is
prone to substantial error, which under most circum-
stances would tend to attenuate an association with PD
risk. In this study, we only had information on air pollu-
tion exposure from 1988 onwards, due to the availability
of the modeled air pollution data. This period covers
only adulthood exposure for our study population. It is
conceivable, although this has not been determined, that
the relevant etiological period may include exposure
during childhood or, more generally, for a longer period
of time than we were able to capture in this study. To
address this issue, we conducted a sensitivity analysis re-
stricted to women who did not move during the study
(with the presumption that those women were also more
likely to maintain a single residence prior to study base-
line) (Table 4). In analyses restricted to women who
maintained the same State and County (430 PD cases)
and in analyzes among women who maintained the same
latitude and longitude (291 PD cases) throughout the
study, our results still did not indicate a significant asso-
ciation between exposure to PM air pollution and risk of
PD (results not shown). Furthermore, because direct meas-
urement data on PM2.5 was only available post-1999, we
conducted sensitivity analyses starting follow-up in 1999
and only using the 311 PD cases onset after January 1 1999.
The results of these analyses did not differ significantly
from our main results.
Another limitation of our study is in the exposure as-
sessment: we did not have personal air pollution mea-
surements in this study or indoor air pollution measures
and we do not know how much time people spend in-
doors vs. outdoors at their address. Due to the large
scale of this study, it was only possible to use indirect
measures of air pollution, collected via GIS-based mod-
eling of pollution based on values measured by monitors
throughout the US. Although the models used to esti-
mate PM in the NHS have been shown to have little bias
and high precision, [37,38] especially when compared
with other methods of estimating air pollution [18,19],
some misclassification of the biologically relevant levels
of individual exposure is inevitable and could have atten-
uated the association between air pollution and PD risk.
Finally, as in most epidemiological studies of a rare dis-
ease such as PD, power and sample size restrict our
ability to detect associations - in this study we had 80%
power to detect relative risks of 1.45 or above, compar-
ing the highest quartile of pollution to the lowest quar-
tile, assuming a 2-sided test with an alpha of 0.05. We
expect that associations below this threshold would
have been seen as suggestive, although not statistically
significant findings. Also, there is also potential for oc-
cupational exposure to air pollution with the nursing
occupation, which we were unable to account for in this
study. Finally, we only had information on residential
address, and were not able to account for exposure to
ambient air pollution during the time that our study
participants spent at work.
The strengths of this study include its’ large size, a
long and prospective follow-up, a high response rate
and the availability of PM10,P M 2.5,P M 10–2.5 estimates
at each woman’s residential address on a monthly basis
throughout the study. The pollution data was available
throughout the continental US, allowing for sufficient
variability to detect a potential contrast in the analyt-
ical categories as well as representativeness of the
pollution levels to which residents of the US are com-
monly exposed.
Conclusion
In summary, overall the results of this large cohort study
of female nurses do not support an effect of air pollution
on PD risk.
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